Joseph Mikhael, MD
Multiple Myeloma Treatment
Joseph Mikhael, MD has treated myeloma patients for over two decades and is a professor at The Translational Genomics Research Foundation (TGen), an affiliate of City of Hope Cancer Center. Dr. Mikhael also serves as the chief medical officer at the International Myeloma Foundation.
He has also led many clinical trials, mostly focused on relapsed/refractory multiple myeloma, and played a role in developing isatuximab, a CD38 monoclonal antibody.
Thank you, Dr. Mikhael, for the work you do and for being so patient-focused!
- Name: Joseph Mikhael, MD
- Professor at TGen
- Chief medical officer at the International Myeloma Foundation
- Experience: ~25 years
- Area of Focus: Multiple myeloma, amyloidosis, Waldenstrom’s macroglobulinemia
Dr. Joseph Mikhael discusses exciting advances in multiple myeloma treatment, including bispecifics and CAR T-cell therapy.
3-drug vs. 4-drug combinations
Multiple myeloma expert Dr. Joseph Mikhael discusses the use of 3-drug vs. 4-drug combinations for front-line treatment.
Multiple Myeloma Screening
Dr. Joseph Mikhael discusses exciting advances in multiple myeloma screening, including new information from the iSTOP and PROMISE clinical trials.